Combined effect of prophylactic lymphadenectomy and long term combination chemotherapy for curatively resected carcinoma of the stomach

1982 ◽  
Vol 12 (4) ◽  
pp. 244-248 ◽  
Author(s):  
Yoshifumi Kodama ◽  
Tadashi Kano ◽  
Ryuichiro Tamada ◽  
Ryunosuke Kumashiro ◽  
Takeshi Okamura ◽  
...  
Keyword(s):  
Combination Chemotherapy ◽  
Combined Effect ◽  
Carcinoma Of The Stomach ◽  
Prophylactic Lymphadenectomy

scholarly journals Simultaneous generalized and low-layer SCIDAR turbulence profiles at san pedro mártir observatory

2019 ◽  
Vol 490 (1) ◽  
pp. 1397-1405 ◽  
Author(s):  
R Avila ◽  
O Valdés-Hernández ◽  
L J Sánchez ◽  
I Cruz-González ◽  
J L Avilés ◽  
...  
Keyword(s):  
High Altitude ◽  
Wind Direction ◽  
Close Agreement ◽  
Baja California ◽  
Ground Level ◽  
Combined Effect ◽  
Moderate Altitude ◽  
San Pedro ◽  
Simultaneous Measurements

ABSTRACT We present optical turbulence profiles obtained with a Generalized SCIDAR (G-SCIDAR) and a low-layer SCIDAR (LOLAS) at the Observatorio Astronómico Nacional in San Pedro Mártir (OAN-SPM), Baja California, Mexico, during three observing campaigns in 2013, 2014, and 2015. The G-SCIDAR delivers profiles with moderate altitude-resolution (a few hundred metres) along the entire turbulent section of the atmosphere, while the LOLAS gives high altitude resolution (on the order of tens of metres) but only within the first few hundred metres. Simultaneous measurements were obtained on 2014 and allowed us to characterize in detail the combined effect of the local orography and wind direction on the turbulence distribution close to the ground. At the beginning of several nights, the LOLAS profiles show that turbulence peaks between 25 and 50 m above the ground, not at ground level as was expected. The G-SCIDAR profiles exhibit a peak within the first kilometre. In 55 per cent and 36 per cent of the nights stable layers are detected between 10 and 15 km and at 3 km, respectively. This distribution is consistent with the results obtained with a G-SCIDAR in 1997 and 2000 observing campaigns. Statistics computed with the 7891 profiles that have been measured at the OAN-SPM with a G-SCIDAR in 1997, 2000, 2014, and 2015 campaigns are presented. The seeing values calculated with each of those profiles have a median of 0.79, first and third quartiles of 0.51 and 1.08 arcsec, which are in close agreement with other long term seeing monitoring performed at the OAN-SPM.

scholarly journals Long-term Survival of Stage IV Melanoma Patients Treated with BOLD Combination Chemotherapy and Intermediate-dose Subcutaneous Interferon-alpha

2018 ◽  
Vol 38 (11) ◽  
pp. 6393-6397 ◽  
Author(s):  
KALLE MATTILA ◽  
PIRITA RAANTA ◽  
VALTTERI LAHTELA ◽  
SEPPO PYRHÖNEN ◽  
ILKKA KOSKIVUO ◽  
...  
Keyword(s):  
Interferon Alpha ◽  
Combination Chemotherapy ◽  
Stage Iv ◽  
Term Survival ◽  
Long Term Survival ◽  
Melanoma Patients ◽  
Stage Iv Melanoma ◽  
Intermediate Dose

scholarly journals Dollar’s Influence on Crude Oil and Gold Based on MF-DPCCA Method

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Zhonghui Ding ◽  
Kai Shi ◽  
Bin Wang
Keyword(s):  
Correlation Analysis ◽  
Crude Oil ◽  
Cross Correlation ◽  
Combined Effect ◽  
Analysis Method ◽  
Correlation Relationship ◽  
Cross Correlation Analysis ◽  
Correlation Analysis Method ◽  
Phase Randomization

This paper analyzed the influence of dollar on crude oil and gold based on the multifractal detrended partial cross-correlation analysis method. It showed that affected by the dollar, the crude oil and gold markets have a partial cross-correlation relationship which is stronger than their own cross-correlation. The partial cross-correlation is long-term and has multifractal characteristics. Through shuffled and Fourier-phase randomization, it is found that this multifractal feature is caused by the combined effect of the long-term cross-correlation between the returns and the fluctuation fat-tailed distribution, where the influence of the fat-tailed distribution is slightly greater than that of the long-term cross-correlation between the returns.

Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer.

1990 ◽  
Vol 8 (1) ◽  
pp. 21-26 ◽  
Author(s):  
M Boyer ◽  
D Raghavan ◽  
P J Harris ◽  
J Lietch ◽  
A Bleasel ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Combination Chemotherapy ◽  
Late Toxicity ◽  
Smoking History ◽  
Diffusing Capacity ◽  
Peripheral Nerve Damage ◽  
Single Breath ◽  
Advanced Testicular Cancer

To date, the prevalence and nature of the late toxicity of cisplatin-based combination chemotherapy for advanced testicular cancer has been poorly documented. Thirty men with a median age of 35 years (range, 23 to 63), who had undergone such treatment were assessed with detailed investigation to determine the type and frequency of chronic toxicity. The median follow-up from the time of commencement of chemotherapy was 75 months (range, 48 to 126). The most common late toxic effects were high tone hearing loss in 23 men (77%) and electrophysiological evidence of peripheral nerve damage in 15 (50%). Both the hearing and nerve abnormalities were predominantly asymptomatic. In addition, elevation of serum cholesterol, noted in 20 patients (67%), was significant (P = .014) when compared with a control population. Hyperuricemia was present in nine patients (30%). Only one patient, with other risk factors (smoking, family history), had evidence of ischaemic heart disease while 20% (all with a smoking history) had a diminished single breath diffusing capacity for carbon monoxide (DLCO). Cisplatin-based chemotherapy is relatively free of major long-term side effects and should not be withheld for fear of late toxicity.

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.

1996 ◽  
Vol 14 (8) ◽  
pp. 2197-2205 ◽  
Author(s):  
P A Greenberg ◽  
G N Hortobagyi ◽  
T L Smith ◽  
L D Ziegler ◽  
D K Frye ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Complete Remission ◽  
Combination Chemotherapy ◽  
Alkylating Agent ◽  
Performance Status ◽  
Metastatic Breast ◽  
Second Primary ◽  
Treatment Protocols

PURPOSE To determine the long-term clinical course of patients with metastatic breast cancer (MBC) who achieved a complete remission with doxorubicin-alkylating agent-containing combination chemotherapy programs. PATIENTS AND METHODS To assess the long-term prognosis of MBC, we reviewed our experience with 1,581 patients treated on consecutive doxorubicin and alkylating agent-containing front-line treatment protocols between 1973 and 1982. Treatment was administered for a maximum duration of 2 years. Characteristics of long-term survivors were evaluated, and hazard rates for progression were calculated. RESULTS From this group, 263 (16.6%) achieved complete responses (CR) and 49 (3.1%) remained in CR for more than 5 years. After a median duration of 191 months, 26 patients remain in first CR, four patients died in CR at times ranging from 118 to 234 months, 18 patients died of breast cancer, and one is alive with metastatic disease. Compared with the overall CR and total patient populations, the long-term CR group had more premenopausal patients, a younger median age, a lower tumor burden, and better performance status. The hazard function shows a substantial drop in risk of progression after approximately 3 years from initiation of therapy. Ten long-term CR patients developed second primary cancers: breast (3), ovary (2), pancreas (1), endometrium (1), colon (1), head and neck (1), and lung (1). CONCLUSION Most patients with MBC treated with systemic therapies have only temporary responses to treatment, but some patients continue in CR following initial treatment. These data show that a small percentage of patients achieve long-term remissions with standard chemotherapy regimens. Remission consolidation strategies are needed.

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

1997 ◽  
Vol 15 (7) ◽  
pp. 2564-2569 ◽  
Author(s):  
S B Saxman ◽  
K J Propert ◽  
L H Einhorn ◽  
E D Crawford ◽  
I Tannock ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Combination Chemotherapy ◽  
Performance Status ◽  
Single Agent ◽  
Phase Iii ◽  
Long Term Follow Up ◽  
Intergroup Trial ◽  
Advanced Urothelial Carcinoma

PURPOSE A previously reported randomized intergroup trial demonstrated that combination chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) was superior to single-agent cisplatin in patients with advanced urothelial carcinoma. We conducted a long-term analysis of patients included in the intergroup trial to examine factors associated with long-term survival. PATIENTS AND METHODS Two-hundred fifty-five assessable patients with urothelial carcinoma were randomized to receive either single-agent cisplatin (70 mg/m2 on day 1) or combination chemotherapy with methotrexate (30 mg/m2 on days 1, 15, and 22), vinblastine (3 mg/m2 on days 2, 15, and 22), doxorubicin (30 mg/m2 on day 2), and cisplatin (70 mg/m2 on day 2). Courses were repeated every 28 days. The association between patient characteristics and survival was assessed using Cox proportional hazards models. RESULTS With long-term follow-up evaluation, survival in the M-VAC arm continues to be superior to cisplatin (P = .00015, log-rank test). Predictors of survival include performance status, histology, and the presence of liver or bone metastasis. Only 3.7% of the patients randomized to M-VAC are alive and continuously disease-free at 6 years. CONCLUSION Long-term follow-up evaluation of the intergroup trial confirms that M-VAC is superior to single-agent cisplatin in patients with advanced urothelial carcinoma; however, durable progression-free survival is rare. Patients with non-transitional-cell histology, poor performance status, and/or bone or visceral involvement fare poorly and are unlikely to benefit significantly from M-VAC chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document